Why did 4506.T stock fall so sharply pre-market?

4506.T stock fell **-23.59%** pre-market on heavy selling and elevated volume (19,183,100 shares). No single firm release drove the move; broad market risk and profit-taking amplified a technical break below the 50-day average. Watch earnings and clinical catalysts for confirmation.

Is Sumitomo Pharma (4506.T) cheap after the drop?

Valuation metrics look low: **P/E 6.36** and ROE **48.92%** suggest attractive earnings power. However higher debt/equity **0.90** and sector P/E **23.43** mean risks remain. Cheap on multiples, but confirm earnings durability before adding exposure.

What price targets and forecasts exist for 4506.T stock?

Meyka AI's forecast model projects a monthly level of **JPY 2,368.14** (+5.67% vs JPY 2,241.00) and a quarterly level of **JPY 2,165.69** (-3.36%). These are model-based projections and not guarantees; use them with risk management and catalyst monitoring.

When is the next catalyst for 4506.T stock to watch?

The next material date is the earnings announcement on **2026-05-13**. Clinical readouts, partner licensing updates, or Roivant-related news are additional catalysts that could reverse or worsen the current sell-off.

JP Stocks

4506.T Sumitomo Pharma (JPX) down 23.59% pre-market: catalysts to watch

ByHuzaifa Zahoor February 24, 2026

Sumitomo Pharma Co., Ltd. (4506.T) plunged -23.59% pre-market to JPY 2,241.00 on heavy volume, putting the stock among Japan’s top losers on the JPX. The move followed a gap lower from the previous close of JPY 2,933.00 and an opening print at JPY 2,425.50. Traders show elevated activity with 19,183,100 shares traded versus an average of 10,781,001, signalling aggressive selling pressure. We assess why 4506.T stock fell, how valuation and technicals reacted, and the near-term scenarios investors should watch.